Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

TOP2A overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	rubitecan Sensitive: D – Preclinical rubitecan Sensitive : D	rubitecan Sensitive: D – Preclinical rubitecan Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	teniposide Sensitive: D – Preclinical teniposide Sensitive : D	teniposide Sensitive: D – Preclinical teniposide Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	etoposide oral Sensitive: D – Preclinical etoposide oral Sensitive : D	etoposide oral Sensitive: D – Preclinical etoposide oral Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	pirarubicin Sensitive: D – Preclinical pirarubicin Sensitive : D	pirarubicin Sensitive: D – Preclinical pirarubicin Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	mitoxantrone Sensitive: D – Preclinical mitoxantrone Sensitive : D	mitoxantrone Sensitive: D – Preclinical mitoxantrone Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	idarubicin hydrochloride Sensitive: D – Preclinical idarubicin hydrochloride Sensitive : D	idarubicin hydrochloride Sensitive: D – Preclinical idarubicin hydrochloride Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	doxorubicin hydrochloride Sensitive: D – Preclinical doxorubicin hydrochloride Sensitive : D	doxorubicin hydrochloride Sensitive: D – Preclinical doxorubicin hydrochloride Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	daunorubicin Sensitive: D – Preclinical daunorubicin Sensitive : D	daunorubicin Sensitive: D – Preclinical daunorubicin Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	aclarubicin Sensitive: D – Preclinical aclarubicin Sensitive : D	aclarubicin Sensitive: D – Preclinical aclarubicin Sensitive : D
TOP2A overexpression	Multiple Myeloma	TOP2A overexpression	Multiple Myeloma	carfilzomib Resistant: D – Preclinical carfilzomib Resistant : D	carfilzomib Resistant: D – Preclinical carfilzomib Resistant : D
TOP2A overexpression	Rectal Cancer	TOP2A overexpression	Rectal Cancer	mitoxantrone Resistant: D – Preclinical mitoxantrone Resistant : D	mitoxantrone Resistant: D – Preclinical mitoxantrone Resistant : D
TOP2A overexpression	Rectal Cancer	TOP2A overexpression	Rectal Cancer	teniposide Resistant: D – Preclinical teniposide Resistant : D	teniposide Resistant: D – Preclinical teniposide Resistant : D
TOP2A overexpression	Rectal Cancer	TOP2A overexpression	Rectal Cancer	epirubicin Resistant: D – Preclinical epirubicin Resistant : D	epirubicin Resistant: D – Preclinical epirubicin Resistant : D
TOP2A overexpression	Rectal Cancer	TOP2A overexpression	Rectal Cancer	idarubicin hydrochloride Resistant: D – Preclinical idarubicin hydrochloride Resistant : D	idarubicin hydrochloride Resistant: D – Preclinical idarubicin hydrochloride Resistant : D
TOP2A overexpression	Rectal Cancer	TOP2A overexpression	Rectal Cancer	daunorubicin Resistant: D – Preclinical daunorubicin Resistant : D	daunorubicin Resistant: D – Preclinical daunorubicin Resistant : D
TOP2A overexpression	Rectal Cancer	TOP2A overexpression	Rectal Cancer	doxorubicin hydrochloride Resistant: D – Preclinical doxorubicin hydrochloride Resistant : D	doxorubicin hydrochloride Resistant: D – Preclinical doxorubicin hydrochloride Resistant : D